Search Within

Elisa De Stanchina

  1. "Alison Schram"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
  3. Research Letter (1)
Groups
  1. Department of Medicine (7)
  2. Department of Pathology and Laboratory Medicine (7)
  3. Early Drug Development Service (7)
  4. GSK Faculty (7)
  5. Gynecologic Medicine Service (7)
  6. Hematology-Oncology Fellows (7)

More Groups

People
  1. Alison Schram (7)
  2. Alexander Drilon (6)
  3. Marc Ladanyi (5)
  4. Marissa Mattar (5)
  5. Romel Somwar (5)
  6. Amanda Kulick (4)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (3)
Publications
  1. Cancer Research (3)
  2. Cancer Discovery (2)
  3. Journal of Thoracic Oncology (1)
  4. Nature Medicine (1)
Publishers
  1. American Association for Cancer Research (5)
  2. Elsevier Inc. (1)
  3. Nature Publishing Group (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
    Journal Article

    Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • The HER2xHER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
    Meeting Abstract

    Odintsov, I.; Khodos, I.; Espinosa-Cotton, M.; Lui, A. J.; Mattar, M.; Schram, A. M.; Schackmann, R. C.; Lammerts van Bueren, J.; Geuijen, C. A.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • TRK XDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Journal Article

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arruabarrena-Aristorena, A.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Meeting Abstract

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arena, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
    Meeting Abstract

    Cocco, E.; Kulick, A.; Misale, S.; Yaeger, R.; Razavi, P.; Won, H. H.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; Cownie, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save